Levosimendan Stada (Levosimendan)

Levosimendan is indicated for conditions where enhanced myocardial contractility and vasodilation are required to support cardiac output.

• Acute decompensated heart failure: improves cardiac output, reduces pulmonary capillary wedge pressure, and alleviates dyspnea and peripheral edema in patients with sudden worsening of heart function.
• Cardiogenic shock (off‑label): provides inotropic support and vasodilation, helping to restore systemic perfusion and blood pressure when conventional catecholamine therapies are insufficient.
• Severe low‑output heart failure: enhances myocardial contractility and reduces afterload, supporting organ perfusion in patients with refractory low‑output states.

• Levosimendan binds to cardiac troponin C, increasing its sensitivity to calcium and thereby augmenting contractile force without raising intracellular calcium concentration. Simultaneously it opens ATP‑sensitive potassium channels in vascular smooth muscle, producing arterial and venous vasodilation. The combined inotropic and vasodilatory actions improve cardiac output while reducing preload and afterload. These effects are dose‑dependent and persist for several hours after infusion due to an active metabolite.

Levosimendan may be associated with a range of adverse reactions, which are categorized by frequency and clinical significance.

Common Side Effects

• Hypotension: transient drop in blood pressure, especially during initial infusion.
• Headache: mild to moderate headache reported during treatment.
• Nausea: occasional nausea or vomiting.
• Tachycardia: increase in heart rate observed in some patients.

Serious or Rare Side Effects

• Severe hypotension: profound blood pressure fall requiring vasopressor support.
• Ventricular arrhythmias: life‑threatening cardiac rhythm disturbances.
• Anaphylactic reaction: rare hypersensitivity with rash, bronchospasm, or shock.

When using Levosimendan, clinicians should observe specific precautions to minimize risk and ensure safe administration.

• Cardiovascular monitoring: continuous blood pressure and ECG monitoring during infusion.
• Concomitant vasodilators: avoid simultaneous high‑dose nitrates or phosphodiesterase inhibitors to prevent excessive hypotension.
• Electrolyte balance: correct hypokalemia or hypomagnesemia before starting therapy.
• Renal or hepatic impairment: adjust dosing or monitor closely in patients with severe organ dysfunction.
• Recent myocardial infarction: use with caution in patients who have had an MI within the past 30 days.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levosimendan can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma concentrations and risk of hypotension.
• Concurrent potent vasodilators (e.g., nitroprusside, high‑dose nitrates): can cause severe hypotension.
• Other inotropic agents (e.g., dobutamine, milrinone): may predispose to arrhythmias.

Moderate Interactions (Monitor Closely)

• Diuretics: may exacerbate electrolyte disturbances, enhancing risk of arrhythmias.
• Beta‑blockers: may blunt the inotropic response, requiring dose adjustment.
• Anticoagulants: additive effect on bleeding risk should be monitored.